Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesRepliCel Life Sciences Inc

RepliCel Life Sciences Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.015 CAD 0.00(0%)
Last update at 2025-02-28T20:58:00Z
VOLUME
269000
Market Cap
1.30M

Momentum Score

…

RepliCel Life Sciences Inc., a regenerative medicine company, focuses on developing autologous cell therapies that treat functional cellular deficits. Its treatments use autologous cell therapy to treat tendon injuries, androgenetic alopecia, and skin aging by restoring cellular function to rejuvenate aging or sun damaged skin, regrow hair, and repair tendons. The company's product candidates include RCH-01, a cell therapy for pattern baldness; RCS-01, a cell therapy foraging or sun damaged skin; and RCT-01, a cell therapy for tendon degeneration. It is also developing DermaPrecise, a dermal injection device. The company has a licensing and collaborative agreement with YOFOTO (China) Health Industry Co. Ltd. to develop and commercialize RCS-01, RCT-01, and DermaPrecise. RepliCel Life Sciences Inc. is based in Vancouver, Canada.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.01
Low
0.01
High
52 Week Price Range
0.01
Low
0.10
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
0.01
Dividend Yield
-
Revenue TTM
0.35M
Revenue Per Share
0.01
Gross Profit TTM
0.35M
Debt / Equity
-0.18
ROE
-
Net Debt
0.75M
ROCE
90.33%
Diluted EPS TTM
-0.02

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -0.31M -0.74M -4.07M -1.58M -3.00M
Net income -0.31M -0.74M -4.07M -1.58M -3.00M
Selling general administrative 1.21M 1.13M 1.51M 0.88M 1.08M
Gross profit 0.35M 0.35M 0.35M 0.35M 0.35M
Reconciled depreciation 0.00M 0.00M 0.00M 0.00M 0.00M
Ebit -1.39M -0.19M -3.17M -1.14M -2.88M
Ebitda -1.38M -0.19M -3.17M -1.14M -2.88M
Depreciation and amortization 0.00M 0.00M 0.00M 0.00M 0.00M
Operating income -1.39M -0.19M -3.17M -1.14M -2.88M
Other operating expenses 1.74M 1.75M 2.65M 1.68M 3.28M
Interest expense 0.15M 0.01M 0.01M 0.18M 0.14M
Interest income 0.00M 0.00M 0.00M 0.00M 0.09M
Net interest income -0.00M -0.01M 0.00M -0.18M -0.09M
Income tax expense -0.00M 1.21M -0.87M 0.18M 0.04M
Total revenue 0.35M 0.35M 0.35M 0.35M 0.35M
Total operating expenses 1.74M 1.75M 2.65M 1.68M 3.28M
Cost of revenue 0.00M - - - -
Total other income expense net 1.07M 0.66M -1.77M -0.25M -0.08M
Net income from continuing ops -0.07M -0.74M -4.07M -1.58M -2.95M
Net income applicable to common shares - - -4.07M -1.58M -3.00M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 0.29M 0.80M 0.59M 0.42M 0.42M
Other current assets 0.05M - - - -
Total liab 4.82M 6.71M 7.43M 5.48M 3.35M
Total stockholder equity -4.53M -5.92M -6.84M -5.06M -2.93M
Other current liab 0.24M 0.69M 0.35M 0.35M 0.35M
Common stock 33.12M - 30.29M 28.47M 27.53M
Capital stock - 31.66M 30.29M 28.47M 28.96M
Retained earnings -43.29M -42.97M -42.23M -38.16M -36.58M
Other liab - - 5.73M 3.21M 3.38M
Other assets 0.00M - 0.20M 0.23M 0.27M
Cash 0.06M 0.41M 0.22M 0.03M 0.02M
Total current liabilities 1.82M 2.07M 1.67M 2.24M 1.55M
Current deferred revenue 0.35M - - - -
Net debt 0.75M - - 0.04M -
Short term debt 0.81M - - - -
Short long term debt - - - 0.05M -
Short long term debt total 0.81M - - - -
Other stockholder equity 5.64M - - - -
Property plant equipment - - 0.00M 0.00M 0.01M
Total current assets 0.16M 0.64M 0.39M 0.19M 0.23M
Net tangible assets - - -6.84M -5.06M -4.43M
Short term investments 0.02M 0.02M 0.02M 0.02M 0.03M
Net receivables 0.04M - 0.06M 0.06M 0.05M
Long term debt - 0.04M 0.03M 0.03M -
Accounts payable 0.42M - 0.60M 1.06M 0.64M
Non currrent assets other -0.00M - - - -
Non current assets total 0.13M 0.16M 0.20M 0.24M 0.20M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments - 0.00M -0.01M 0.01M -0.03M
Change to liabilities - - -0.30M 0.87M 0.03M
Total cashflows from investing activities - - - 0.01M -0.03M
Net borrowings - - - 0.11M 0.11M
Total cash from financing activities 1.06M 1.60M 2.70M 0.76M 0.42M
Change to operating activities - - -0.02M 0.05M 0.42M
Net income -0.31M -0.74M -4.07M -1.58M -3.00M
Change in cash -0.35M 0.19M 0.19M 0.01M -2.39M
Begin period cash flow 0.41M 0.22M 0.03M 0.02M 2.42M
End period cash flow 0.06M 0.41M 0.22M 0.03M 0.02M
Total cash from operating activities -1.41M -1.41M -2.51M -0.77M -2.78M
Issuance of capital stock 2.20M 1.60M 1.07M 0.66M 0.42M
Depreciation 0.00M 0.00M 0.00M 0.00M 0.00M
Change to inventory - -0.30M 0.30M -0.85M -
Change to account receivables 0.04M -0.02M 0.00M -0.01M 0.03M
Other cashflows from financing activities - - 2.70M 0.15M 0.83M
Change to netincome - - 1.88M -0.10M -0.22M
Capital expenditures 0.00M 0.00M 0.00M 0.00M 0.00M
Change in working capital 0.03M 0.27M -0.32M 0.92M 0.44M
Stock based compensation 0.28M 0.07M 0.47M 0.00M 0.03M
Other non cash items -1.09M -1.59M 0.56M -0.28M -0.29M
Free cash flow -1.41M -1.41M -2.51M -0.77M -2.78M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(CAD)
Price
(CAD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
RP
RepliCel Life Sciences Inc		 -
-%		 0.01 - - 3.68 - 3.70 -2.78
SHRX
Sharp Therapeutics Corp.		 -
-%		 1.37 - - - 32.37 - -
NRX
NurExone Biologic Inc.		 -0.02
4.00%		 0.48 - 6.90 - 15.26 - -7.24
MIR
MedMira Inc		 -
-%		 0.06 - - 223.37 - 293.42 -80.03
TTI
Thiogenesis Therapeutics Corp.		 -
-%		 0.63 - - - 15.17 - -58.16

Profile*

RepliCel Life Sciences Inc

RepliCel Life Sciences Inc., a regenerative medicine company, focuses on developing autologous cell therapies that treat functional cellular deficits. Its treatments use autologous cell therapy to treat tendon injuries, androgenetic alopecia, and skin aging by restoring cellular function to rejuvenate aging or sun damaged skin, regrow hair, and repair tendons. The company's product candidates include RCH-01, a cell therapy for pattern baldness; RCS-01, a cell therapy foraging or sun damaged skin; and RCT-01, a cell therapy for tendon degeneration. It is also developing DermaPrecise, a dermal injection device. The company has a licensing and collaborative agreement with YOFOTO (China) Health Industry Co. Ltd. to develop and commercialize RCS-01, RCT-01, and DermaPrecise. RepliCel Life Sciences Inc. is based in Vancouver, Canada.

570 Granville Street, Vancouver, BC, Canada, V6C 3P1

604 248 8730

https://www.replicel.com

Name Title Year Born
Mr. Andrew Schutte Pres, CEO & Director 1990
Dr. Kevin John McElwee Ph.D. Co-Founder & Chief Scientific Officer 1970
Mr. Simon S. Ma B.A., CPA, CA Chief Financial Officer 1965
Dr. Rolf Hoffmann M.D. Chief Medical Officer & Member of Clinical Advisory Board 1962
Mr. R. Lee Buckler B.Ed., L.L.B., LLB Corp. Sec. & Director 1966
Ben Austring Chief Legal Officer & Operations Mang. NA
Mr. Darrell Panich M.Sc, PMP, CPM Clinical Consultant 1972
Mr. Andrew Schutte President, CEO & Director 1990
Mr. Ben Austring Chief Legal Officer, Corporate Secretary & COO NA
Mr. David Kwok CPA Chief Financial Officer NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

THX
CAD 1.01
+9.78%
LIF
CAD 21.88
+7.84%
CIA
CAD 2.04
+6.25%
MDA
CAD 38.77
+5.76%
SXGC
CAD 8.56
+5.42%
GIL
CAD 46.32
-23.36%
NOA
CAD 12.40
-22.50%
ITH
CAD 1.95
-20.08%
TNZ
CAD 53.00
-14.24%
LSPD
CAD 14.00
-13.26%

Equity Sectors*

  • Basic Materials

    +0.02%

  • Communication Services

    +1.01%

  • Consumer Cyclical

    -1.14%

  • Consumer Defensive

    -0.06%

  • Energy

    -0.86%

  • Financial Services

    -0.32%

  • Healthcare

    -0.69%

  • Industrials

    -1.25%

  • Real Estate

    +0.16%

  • Technology

    -1.66%

  • Utilities

    -0.04%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…